Thrombotic microangiopathy caused by interferon β-1b for multiple sclerosis: a case report
Tóm tắt
Từ khóa
Tài liệu tham khảo
Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Fremeaux-Bacchi V. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15–39.
Clark WF. Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange. Semin Dial. 2012;25:214–9.
Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, Szczepiorkowski ZM, Williams ME, Wu Y, Shaz BH. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013;28:145–284.
Larochelle C, Grand’maison F, Bernier GP, Latour M, Cailhier JF, Prat A. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon beta. Mult Scler. 2014;20:1783–7.
Olea T, Diaz-Mancebo R, Picazo ML, Martinez-Ara J, Robles A, Selgas R. Thrombotic microangiopathy associated with use of interferon-beta. Int J Nephrol Renovasc Dis. 2012;5:97–100.
Mahe J, Meurette A, Moreau A, Vercel C, Jolliet P. Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis. Drug Des Devel Ther. 2013;7:723–8.
Vosoughi R, Marriott JJ. Thrombotic microangiopathy in interferon beta treated multiple sclerosis patients: review of literature and report of two new cases. Mult Scler Relat Disord. 2014;3:321–5.
Jadoul M, Piessevaux H, Ferrant A, Cosyns JP, de Strihou CVY. Renal thrombotic microangiopathy in patients with chronic myelogenous leukaemia treated with interferon-alpha 2b. Nephrol Dial Transplant. 1995;10:111–3.
Galesic K, Bozic B, Racic I, Scukanec-Spoljar M. Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myeloid leukaemia. Nephrology (Carlton). 2006;11:49–52.
Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987;47:5155–61.
Wu WZ, Sun HC, Shen YF, Chen J, Wang L, Tang ZY, Iliakis G, Liu KD. Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J Cancer Res Clin Oncol. 2005;131:169–78.
Arrambide G. Thrombotic thrombocytopenic purpura-haemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon beta. Mult Scler. 2014;20:1788–9.
Orvain C, Augusto JF, Besson V, Marc G, Coppo P, Subra JF, Sayegh J. Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis. Int Urol Nephrol. 2014;46:239–42.
Broughton A, Cosyns JP, Jadoul M. Thrombotic microangiopathy induced by long-term interferon-beta therapy for multiple sclerosis: a case report. Clin Nephrol. 2011;76:396–400.
Hunt D, Kavanagh D, Drummond I, Weller B, Bellamy C, Overell J, Evans S, Jackson A, Chandran S. Thrombotic microangiopathy associated with interferon beta. N Engl J Med. 2014;370:1270–1.
Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998–2008. Intern Med. 2010;49:7–15.
Carson JM, Newman ED, Farber JL, Filippone EJ. Tacrolimus-induced thrombotic microangiopathy: natural history of a severe, acute vasculopathy. Clin Nephrol. 2012;77:79–84.
Aruch DB, Renteria A. Simultaneous PRES and TMA secondary to tacrolimus after allogeneic bone marrow transplant. Blood. 2015;125:3963.